Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.4% – Here’s Why

Eli Lilly and Company (NYSE:LLY) traded up 1.4% on Wednesday . The company traded as high as $922.15 and last traded at $915.7140. 2,155,156 shares were traded during trading, a decline of 33% from the average session volume of 3,195,379 shares. The stock had previously closed at $903.02.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Long‑term AD data: EBGLYSS (lebrikizumab‑lbkz) showed durable skin clearance and itch relief for up to four years in the ADlong Phase 3b open‑label extension — supports recurring, once‑monthly maintenance use and strengthens non‑GLP‑1 growth prospects; data to be presented at the AAD meeting. Lilly PR Newswire: EBGLYSS 4‑year data
• Positive Sentiment: Analyst upgrades: Erste Group has nudged up FY2026/27 EPS forecasts for LLY, signaling improved sell‑side expectations for earnings power. MarketBeat: LLY analyst notes
• Positive Sentiment: Brokerage sentiment remains constructive — coverage shows an average rating of “Moderate Buy,” which provides support for demand into any weakness. American Banking News: Moderate Buy rating
• Neutral Sentiment: Fund commentary: Janus Henderson’s “Forty Fund” update highlights broader market stability and earnings momentum — context that can help LLY sentiment but is not LLY‑specific. InsiderMonkey: Janus Henderson Forty Fund
• Neutral Sentiment: Industry positioning: Research reports flag Lilly as a major player in expanding oncology and mAb markets — positive long‑term but incremental near‑term impact. Yahoo Finance: Anti‑Cancer MAbS Market Report
• Neutral Sentiment: Trending coverage: Zacks and other outlets note LLY is a trending ticker — increases visibility/flow but can amplify short‑term volatility. Zacks: Why LLY is trending
• Negative Sentiment: Obesity‑market competitive pressure: Coverage comparing Lilly vs. Novo Nordisk emphasizes Novo’s current lead in obesity drugs, keeping investor focus on market share risks for Lilly’s GLP‑1 portfolio. Fool: Lilly vs Novo Nordisk
• Negative Sentiment: Peer progress in obesity: Viking Therapeutics finishing enrollment in a late‑stage obesity trial highlights rising competition and keeps near‑term market share uncertainty elevated. Yahoo Finance: VKTX enrollment
• Negative Sentiment: Acquisition/rumor noise: Speculation about Lilly‑linked deals (e.g., MDGL buyout chatter) can create headline‑driven swings and distract from fundamentals. MSN: MDGL buyout speculation

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on LLY shares. Guggenheim raised their target price on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Jefferies Financial Group set a $1,300.00 price target on Eli Lilly and Company and gave the company a “buy” rating in a research note on Friday, March 13th. Scotiabank reiterated an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Daiwa Securities Group upped their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,221.44.

Eli Lilly and Company Stock Down 2.1%

The firm has a market capitalization of $829.65 billion, a P/E ratio of 38.26, a PEG ratio of 1.06 and a beta of 0.40. The firm’s 50 day moving average is $1,010.46 and its two-hundred day moving average is $960.96. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter last year, the firm posted $5.32 EPS. The company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at $25,000. Sumitomo Mitsui Financial Group Inc. bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $27,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares in the last quarter. Finally, Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth $29,000. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.